Shares of Nasus Pharma Ltd. (NYSE: NSRX) are trading down 9.03 percent ahead of the open after disclosing Positive Phase 2 results for NS002.
Nasus Pharma announced positive results from its Phase 2 clinical trial for NS002, an intranasal epinephrine powder designed for the treatment of anaphylaxis.
The study demonstrated that NS002 achieved faster and higher early absorption of epinephrine compared to the widely used EpiPen® autoinjector.
The company has indicated plans to initiate a pivotal clinical trial for NS002 in late 2026, marking a significant step forward in the development of this potential alternative treatment for anaphylaxis.
Nasus Pharma Ltd. traded near $2.82 in early trading after closing the prior session at $3.10.
 are moving down 9.03 percent ahead of the open after disclosing Positive Phase 2 results for NS002.){kind=link}